The length of telomeres and other biological indicators of the aging process were determined (blood test with a leukocyte formula, the condition and functioning of the immune system, the condition of the kidneys, liver, endocrine system, cholesterol, glucose metabolism, the state of the cardiovascular system, bones, skin, eyesight)
52% of participants took OYOX, 48% took placebo
The initial evaluation of the obtained clinical data was carried out by experts, the final data analysis was additionally processed using artificial intelligence - the ATECH neural network- in order to identify the deep relationships of the monitored parameters.
Evaluation was performed before the start of the study and after 1, 3, 6, and 12 months after taking OYOX
980 people, age range 30-87 years; 58% men, 42% women
| Before taking | After 2 months | |||
| Row 1 | Row 2 | Row 3 | Row 4 | |
| m | f | m | f | sex |
| 42-68 | 40-53 | 42-68 | 40-53 | age |
| 5,4 | 5,3 | 9,2 | 8,9 | telomere length measurement, kb |
| 7,7 | 7,7 | 9,4 | 11,2 | RTL Index |
| 4,8 | 4,5 | 4,1 | 3,8 | CRP, mg /l |
| 6,23 | 5,9 | 4,8 | 5 | Total cholesterol, mmol/l |
| 3,3 | 2,8 | 2,2 | 1,7 | LDL, mmol/l |
| 0,7 | 0,9 | 1,5 | 1,8 | HDL, mmol/l |
| 5,6 | 5,4 | 4,9 | 5 | glycosylated hemoglobin (HbA1c,%) |
| 94 | 94 | 88 | 76 | creatinine (NKF, 2001), μmol/L |
| 9,3 | 12 | 7,9 | 9 | total bilirubin, mmol/l |
| 22 | 19 | 18 | 17 | ALT Unit/L |
| 19 | 19 | 16 | 18 | AST Unit/L |
| OYOX | Placebo | |||||||
| Before taking | After 3 months | Before taking | After 3 months | |||||
| Row 1 | Row 2 | Row 3 | Row 4 | Row 5 | Row 6 | Row 7 | Row 8 | |
| m | f | m | f | m | f | m | f | sex |
| 45-67 | 42-59 | 45-67 | 42-59 | 46-66 | 43-54 | 46-66 | 43-54 | age |
| 4,4 | 5,4 | 10,1 | 9,4 | 4,8 | 4,7 | 4,8 | 4,5 | telomere length measurement, kb |
| 7,3 | 8,4 | 12 | 11,8 | 7,9 | 8,2 | 6,2 | 7,9 | RTL Index |
| 4,3 | 4,8 | 3 | 2,9 | 4,4 | 4,9 | 4,5 | 4,8 | CRP, mg /l |
| 5,2 | 5 | 4,8 | 4,6 | 5 | 4,6 | 5,3 | 4,9 | Total cholesterol, mmol/l |
| 2,8 | 3,1 | 2 | 2,2 | 2 | 2,4 | 2 | 2,3 | LDL, mmol/l |
| 0,7 | 1 | 1,5 | 1,7 | 0,9 | 1,9 | 1 | 1,9 | HDL, mmol/l |
| 5,8 | 5,7 | 4,6 | 5,1 | 5,9 | 5,6 | 5,8 | 5,8 | glycosylated hemoglobin (HbA1c,%) |
| 98 | 96 | 80 | 77 | 98 | 105 | 100 | 101 | creatinine (NKF, 2001), μmol/L |
| 10,8 | 12,2 | 9,6 | 9,8 | 11,3 | 11,9 | 11,2 | 11,5 | total bilirubin, mmol/l |
| 23 | 26 | 20 | 19,2 | 28 | 31 | 28 | 31 | ALT Unit/L |
| 29 | 30 | 28 | 20 | 23 | 28 | 24 | 27 | AST Unit/L |
| OYOX | Placebo | |||||||
| Before taking | After 6 months | Before taking | After 6 months | |||||
| Row 1 | Row 2 | Row 3 | Row 4 | Row 5 | Row 6 | Row 7 | Row 8 | |
| m | f | m | f | m | f | m | f | sex |
| 45-67 | 42-59 | 45-67 | 42-59 | 46-66 | 43-54 | 46-66 | 43-54 | age |
| 7,9 | 8,1 | 12,3 | 10,4 | 7,3 | 7,9 | 7,5 | 7,2 | telomere length measurement, kb |
| 10,4 | 11,5 | 15,4 | 13,3 | 8,2 | 9,4 | 9 | 8,3 | RTL Index |
| 4,2 | 4,1 | 2,5 | 2,9 | 4,3 | 3,8 | 5,4 | 2,6 | CRP, mg /l |
| 5,4 | 5,8 | 4,8 | 5 | 5,9 | 4,9 | 6 | 5,4 | Total cholesterol, mmol/l |
| 2,8 | 2,6 | 2 | 1,8 | 2,8 | 1,9 | 3 | 1,8 | LDL, mmol/l |
| 1,3 | 1,4 | 2 | 1,8 | 1,5 | 1,6 | 1,4 | 1,3 | HDL, mmol/l |
| 5,8 | 5,6 | 4,9 | 5 | 5,3 | 5,9 | 5,5 | 5,4 | glycosylated hemoglobin (HbA1c,%) |
| 100 | 98 | 90 | 85 | 112 | 99 | 111 | 102 | creatinine (NKF, 2001), μmol/L |
| 12,8 | 10,7 | 10,2 | 9,4 | 11,6 | 10,9 | 11,8 | 10,2 | total bilirubin, mmol/l |
| 25 | 19 | 22 | 16 | 22 | 28 | 23 | 27 | ALT Unit/L |
| 22 | 21 | 19,5 | 20 | 25 | 26,7 | 25,2 | 27,1 | AST Unit/L |
In the group of people taking OYOX, it was reliably noted:
- Statistically significant decrease in the percentage of short telomeres (p = 0.029).
- Decrease in the percentage of aging cytotoxic (CD8+/CD28-) T-cells (1.5%; 4.4%; 8.6% and 7.5% after 1, 3.6 and 12 months).
- Improvement of lipid and carbohydrate metabolism, glycosylated hemoglobin (HbA 1%) 4.9% (p = 0.01), total cholesterol 5.7 mmol / l (p = 0.003) low density lipoproteins (LCL-C) - 3, 82 mmol / L (p = 0.0021) homocysteine-3.4 mmol / L (p = 0.001) For the reduced systolic and diastolic blood pressure, the dynamics was 17.1-4.2 mm Hg. (p = 0.006 and 0.002, respectively).
- After 8 months, bone mineral density increased by 2% (p=0.002).
- OYOX was not associated with the development of side effects.
1. The “CYC-8” stimulated effect of increased activity of sirtuins in MNPKs of donors of the age group of 30-35 years was relatively moderate in the range from 1.5 to 2.5 times. "CYC-8" significantly increased the activity of sirtuins in MNPKs of the age group 36-55 years from 3.5 to 7 times. In the age group of 57-87 years, the activity of sirtuins increased from 2.5 times -14 times.
2. Within a few minutes after contact with CYC-8, the MAPK/ERK pathway is activated, followed by an increase in the production of SIRT1 gene sirtuins; 3; 6 (with a maximum of 12 hours) of activation reaches a maximum after 16-48 hours.
3. A short 7-day exposure of “CYC-8” to CD4 + CD8 + T-lymphocytes led to a small, but statistically significant increase in the number of doubling of the population compared to control untreated cells.
4. As a result of the work, no evidence was obtained that the use of “CYC-8” contributed to the loss of growth control and transformation in the culture of the studied cells. Moreover, “CYC-8” does not lead to any significant increase in the constitutive activity of sirtuins in a healthy young age group of 22-28 years.
5. An increase in the cytobiochemical marker of the number and activity of mitochondria in peripheral blood lymphocytes was found, which confirms the realization of increased activity of sirtuins 1,3,6 at the level of mitochondriogenesis.
Patients during the epidemic rise of COVID-19 in the clinical recovery phase. Design of a clinical study of the effectiveness of OYOX in the rehabilitation of patients undergoing COVID-19 complicated by pneumonia and changes in the cytokine profile: prospective, open, comparative. The control group was not formed for ethical reasons. In order to compare groups according to the main criteria of effectiveness, the case histories of 30 patients not receiving OYOX during the convalescence period were analyzed. All patients underwent symptomatic therapy. The study was carried out in accordance with the ethical standards provided for by the Declaration of the XVIII World Medical Assembly (Helsinki June1964).
The group that took the OYOX course during the convalescence period included the following participants:An analysis of the obtained objective data and dynamic monitoring of the general well-being of the patients suggest that OYOX is highly effective in the rehabilitation of patients with COVID-19.
After 30 days of taking OYOX:Evaluation of the effectiveness of OYOX was established when the pulmonary pattern was completely restored after the virus-induced pneumonia, and the absence of pathological compaction of the lung tissue (confirmed by a CT scan of the chest organs) positive dynamics and normalization of biochemical laboratory parameters of blood and immune status significant improvement in well-being and disability recovery.
The use of OYOX in the rehabilitation of patients undergoing COVID-19 complicated by pneumonia and changes in the cytokine profile has convincingly shown a reduction in rehabilitation time. Participants taking OYOX noted a significant improvement in well-being, normalization of sleep, the absence of signs of fatigue already at 7-10 days from the start of treatment. Positive dynamics of the restoration of pulmonary pattern during CT-scan was observed on the 12th day after taking OYOX.